A Phase I Safety and Pharmacokinetic Study of CVM-1118 Extended-Release Capsules Administered Orally to Patients With Advanced Cancers
Latest Information Update: 30 Nov 2022
At a glance
- Drugs Foslinanib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors TaiRx
- 25 Nov 2022 Status changed from active, no longer recruiting to completed.
- 07 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 07 May 2020 Planned initiation date changed from 1 Apr 2020 to 6 May 2020.